<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629172</url>
  </required_header>
  <id_info>
    <org_study_id>P15-336</org_study_id>
    <nct_id>NCT02629172</nct_id>
  </id_info>
  <brief_title>Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1</brief_title>
  <official_title>Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety and effectiveness of
      paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily
      practice in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of Participants with Sustained Virologic Response (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Sustained Virologic Response (SVR24)</measure>
    <time_frame>24 weeks after the last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification 24 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Failure After Treatment</measure>
    <time_frame>Post-treatment 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed quantifiable hepatitis C virus ribonucleic acid (HCV RNA) at the end of 12 week treatment but subsequent viremia with HCV RNA greater than or equal to the lower limit of quantitation during follow-up period of 24 weeks after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Failure During Treatment</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA levels reach less than the lower limit of quantitation (LLOQ), then increase to greater than or equal to the LLOQ at any point during treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)</arm_group_label>
    <description>Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis C
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HCV genotype 1 patients treated with paritaprevir/ritonavir/ombitasvir in daily practice

        Exclusion Criteria:

        Patients who have been previously treated with paritaprevir/ritonavir/ombitasvir
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsu Kamitani, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie GK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie Japan PMOS Desk</last_name>
    <phone>+81-3-4577-1125</phone>
    <email>AbbVie_JPN_info_clingov@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takako Sugita, BA</last_name>
    <email>takako.sugita@abbvie.com</email>
  </overall_contact_backup>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 10, 2015</lastchanged_date>
  <firstreceived_date>December 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 1</keyword>
  <keyword>Paritaprevir</keyword>
  <keyword>Hepatitis C Virus (HCV)</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Ombitasvir</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
